Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — FY2023 Earnings Presentation

44 slides from Aspen Pharmacare's earnings presentation, Aug 31, 2023

  1. Slide 1: FY 2023 Annual Results

    ») ti FY 2023 ANNUAL RESULTS 31 AUGUST 2023 Healthoare wecare © aspen

  2. Slide 2: Disclaimer

    DISCLAIMER CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS  We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.

  3. Slide 3: Performance Review

    DE. PERFORMANCE REVIEW Healthcare. We Care. 6) aspen tnt rn nnn n nt NN SSNs nus 0 0000000000000

  4. Slide 4: Highlights from FY 2023 Operational Performance

    HIGHLIGHTS FROM FY 2023 OPERATIONAL PERFORMANCE MEETING EBITDA GUIDANCE GUIDANCE  FY 2023 EBITDA to align with prior year’s performance at R11bn  Needed a record H2, as » In H1, EBITDA ↓ 11% on revenue also ↓ on prior year  Material EBITDA losses relative to the prior year included: » COVID vacci

  5. Slide 5: FY 2023 Operational Performance Highlights

    FY 2023 OPERATIONAL PERFORMANCE HIGHLIGHTS RECORD SECOND HALF DELIVERY We achieved R21bn in sales, which represents our highest-ever achievement of H2 sales » Normalised EBITDA for H2 was also a record over R6.6bn H2 2023 vs H2 2022 reported revenue » Commercial Pharma +11% » Regional brands +9% » S

  6. Slide 6: Group Revenue

    GROUP REVENUE % change R'million FY 2023 FY 2022 Reported CERǂ Commercial Pharma 29 412 27 658 6% -1% Regional Brands 18 824 17 405 8% 1% Sterile Focus Brands 10 588 10 253 3% -6% Manufacturing 11 297 10 948 3% -6% Group revenue 40 709 38 606 5% -3%  Excluding impact of prior year divestment of R1.

  7. Slide 7: Commercial Pharma | Regional Brands

    COMMERCIAL PHARMA | REGIONAL BRANDS REVENUE % change R’million FY 2023 FY 2022 Reported CERǂ Africa Middle East 7 711 7 878 -2% -3% Australasia 5 150 4 464 15% 7% Americas 3 452 2 856 21% 2% Europe CIS 1 774 1 594 11% 2% Asia 737 613 20% 9% Regional Brands 18 824 17 405 8% 1%  Growth momentum achie

  8. Slide 8: Commercial Pharma | Steriles

    COMMERCIAL PHARMA | STERILES REVENUE % change R’million FY 2023 FY 2022 Reported CERǂ Asia 4 768 4 503 6% -3% Europe CIS 3 073 3 143 -2% -11% Americas 1 627 1 439 13% -2% Australasia 677 643 5% -3% Africa Middle East 443 525 -16% -18% Sterile Focus Brands 10 588 10 253 3% -6%  Strong rebound from H

  9. Slide 9: Manufacturing

    MANUFACTURING REVENUE % change R’million FY 2023 FY 2022 Reported CERǂ API 5 024 4 894 3% -6% Heparin 3 423 2 379 44% 33% FDF - Steriles 1 480 2 567 -42% -47% FDF - Other 1 370 1 108 24% 13% Manufacturing 11 297 10 948 3% -6%  Manufacturing in H2 grew 15% (+0% CER)  H1 reported revenue -10% (-12%

  10. Slide 10: Financial Review

    FINANCIAL REVIEW Healthcare. We Care. © aspen nnn 00 000000

  11. Slide 11: Financial Highlights

    FINANCIAL HIGHLIGHTS RECORD H2 REBOUND ON REVENUE AND EBITDA AS GUIDED INCREASED NET FINANCE COSTS REDUCES NHEPS GROWTH BY 141 CENTS (-9%) -3% CERⱡ -6% CERⱡ -15% CERⱡ +5% +1% -8% 1 628 40 709 11 100 11 012 1 499 38 606 +13% +18% +20% 21 559 6 017 19 150 819 5 083 680 FY 2022 H1 2023 H2 2023 FY 2023

  12. Slide 12: Financial Highlights

    FINANCIAL HIGHLIGHTS 5% INCREASE IN DIVIDEND DECLARED SUPPORTED BY IMPROVED OPERATING CASH FLOW +5% -1% +9% +5% 1 243 FX 18.6 88% 1 186 18.4 342 326 81% 1.9X 1.9X 16.1 FY 2022 FY2023 FY 2022 FY2023 FY 2022 FY2023 FY 2022 FY2023 Net Borrowings (CER) ⱡ Operating cash flow per Operating cash Dividend p

  13. Slide 13: Financial Highlights

    FINANCIAL HIGHLIGHTS HIGHEST REPORTED H2 REVENUE & NORMALISED EBITDA FROM CONTINUING OPERATIONS 21 559 19 225 19 133 17 690 15 211  H2 2023 revenue up +12% on H2 2022 » Commercial Pharma revenue up +11% » Manufacturing revenue up +15%  Currency tailwinds are a big factor  On a CER basis, revenue

  14. Slide 14: Gross Profit Percentage

    GROSS PROFIT PERCENTAGE | CERǂ AT YTD JUNE 2023 RATES RESILIENT AND IMPROVING COMMERCIAL PHARMA GROSS PROFIT MARGINS Regional Brands Sterile Focus Brands 59.7% 59.6% 59.6% 60.8% 60.6% 60.5% 60.0% 56.5% Favourable sales mix and cost Site transfer savings improve of goods savings more than FY 2023 tre

  15. Slide 15: Normalised EBITDA

    NORMALISED EBITDA REPORTED EBITDA IN LINE WITH FY 2022 AS GUIDED R'million FY 2023 % of revenue FY 2022 % of revenue % change % change CERǂ Revenue 40 709 100.0% 38 606 100.0% 5% -3% Gross profit* 18 934 46.5% 18 306 47.4% 3% -4% Depreciation 1 247 3.1% 1 167 3.0% 7% 0% Operating expenses (9 426) 23

  16. Slide 16: Net Financing Costs

    NET FINANCING COSTS SIGNIFICANT FOREX LOSSES IN A VOLATILE MARKET EM currencies against EUR: 2023 R’million FY 2023 H2 2023 H1 2023 FY 2022 2 1.9 Net interest paid (591) (338) (253) (468) 1.8 1.7 1.6 Effective interest rate for the 1.5 3.21% 3.55% 2.83% 2.92% 1.4 period* 1.3 1.2 1.1 Foreign exchange

  17. Slide 17: Working Capital

    WORKING CAPITAL INCREASED HEPARIN INVESTMENT TO SUPPORT VIATRIS LATAM TRANSACTION Operating cash conversion cycle +11% Cash out flow 250% +R3 358m 200% 201% 2 701 657 -1 165 150% 22 210 922 Commercial Pharma 117% 115% 100% Heparin 1 064 50% 50% 58% 20 017 715 Other Manufacturing 0% H2 2021 H1 2022 H

  18. Slide 18: Delivering on Our ESG Commitments

    DELIVERING ON OUR ESG COMMITMENTS » Access to affordable high-quality medicines across a broad geography including more than 60 low- and middle- Patient income countries » Progression against milestones in strategic position paper on access to medicines^ » Technical transfer of 4 vaccines from The S

  19. Slide 19: Strategic Review

    STRATEGIC REVIEW veaimone ecw @ aspen ttn ttt nnn U NN rnttttttssttttssttstt0000t0sstss 0s stuusnnnn

  20. Slide 20: Core Strategic Commercial Objectives

    CORE STRATEGIC COMMERCIAL OBJECTIVES THE BIG FIVE Commercial Pharma Manufacturing  Drive organic growth  Contracts closed to be converted into material » Commercial Pharma has performed in spite of contributors to the Group no capital allocated over last 4 years » Have built a relevant globally si

  21. Slide 21: Commercial Pharma | Incremental Growth Drivers

    COMMERCIAL PHARMA | INCREMENTAL GROWTH DRIVERS SOUTH AFRICA | BENEFIT OF FOOTPRINT SA Commercial business has a respected, professional and capable footprint across Southern Africa Partnering with multinationals provides mutual benefits by significantly outperforming a small standalone local entity

  22. Slide 22: Commercial Pharma | Growth Drivers

    COMMERCIAL PHARMA | GROWTH DRIVERS LATAM OPPORTUNITY | BUILDING THE FOOTPRINT Team rewarded for sustained performance  Double digit CAGR growth over past 7 years Key household brands bolted-on to region with demonstrated capability  Growing, post-patent/lifestyle brands with loyal support  Line e

  23. Slide 23: Commercial Pharma | China Strategy

    COMMERCIAL PHARMA CHINA | STRATEGY FOR FUTURE FOOTPRINT Potential to be the largest by Last material wrinkle in Numerous other companies Aspen is in advanced country value in Aspen Commercial Pharma also impacted by VBP negotiations on some exciting opportunities » Expected in the short to » Project

  24. Slide 24: Manufacturing | 2024 Background

    MANUFACTURING 2024 BACKGROUND API business  Business has rebounded and approaching pre-COVID levels  Business rebound to be sustained Heparin  Anticipate strong downward pricing adjustments in raw materials and pricing, will drive down selling prices  Certainty through committed Viatris offtake

  25. Slide 25: Manufacturing | Sterile Manufacturing Agreements

    MANUFACTURING STERILE MANUFACTURING AGREEMENTS South Africa  Insulin franchise for major multinational » Material global volumes including Africa  Serum Institute » Focus on Gavi volumes for Africa Further material volumes for both France and SA under discussion France  Three agreements signed wi

  26. Slide 26: Manufacturing | Guidance

    MANUFACTURING GUIDANCE At the half year we guided R2bn of contribution for CY 2024 and R4bn for CY 2025  Contribution conversion of at least 70% to EBITDA  This guidance is maintained  Working positively to grow this base with additional contracted volumes For FY 2024 we expect gross margin in Ma

  27. Slide 27: Summary and Prospects

    SUMMARY AND PROSPECTS FY 2024 PERFORMANCE  Aspen has strong short to medium growth prospects OUTLOOK » For both Commercial Pharma and Manufacturing COMMERCIAL  Double digit growth in reported revenue^ PHARMA » Driven by organic growth » Recent transactions in Latam and Sub-Saharan Africa » China t

  28. Slide 28: Guidance and Prospects | H2 2024 Inflection Point

    GUIDANCE AND PROSPECTS H2 2024 | THE INFLECTION POINT FY 2024  Growth for FY 2024 projected » Led by double digit reported revenue growth from Commercial Pharma » Results heavily weighted to H2 H1 2024  H1 - in line with prior year reported results » China VBP impacts » Prior year had grants H2 20

  29. Slide 29: Appendices

    2=... APPENDICES | Healthcare. We Care. 6) aspen

  30. Slide 30: Abridged Statement of Comprehensive Income

    APPENDIX 1 | ABRIDGED STATEMENT OF COMPREHENSIVE INCOME R’million FY 2023 FY 2022 % change H1 2023 Net revenue 40 709 38 606 5% 19 150 Cost of sales (21 775) (20 300) (10 184) Gross profit 18 934 18 306 3% 8 966 Gross profit margin 46.5% 47.4% 46.8% Operating expenses (9 426) (8 539) (4 621) Other o

  31. Slide 31: Abridged Statement of Normalised Comprehensive Income

    APPENDIX 2 | ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME R’million FY 2023 FY 2022 % change FY 2022 (CERǂ) % change (CERǂ) H1 2023 Net revenue 40 709 38 606 5% 41 817 -3% 19 150 Cost of sales (21 775) (20 300) 7% (22 092) -1% (10 184) Gross profit 18 934 18 306 3% 19 725 -4% 8 966 Gross pr

  32. Slide 32: Reconciliation of Reported to Normalised EBITDA

    APPENDIX 3 | RECONCILIATION OF REPORTED TO NORMALISED EBITDA R’million FY 2023 FY 2022 % change H1 2023 Net revenue 40 709 38 606 5% 19 150 Cost of sales (21 775) (20 300) (10 184) Gross profit 18 934 18 306 3% 8 966 Operating expenses (9 426) (8 539) (4 621) Other operating expenses (2 382) (3 046)

  33. Slide 33: Reconciliation of NHEPS

    APPENDIX 4 | RECONCILIATION OF NHEPS FY 2022 % change Cents FY 2023 FY 2022 % change H1 2023 (CERǂ) (CERǂ) Basic earnings per share (EPS) 1 176.9 1 432.3 -18% 1 523.1 -23% 602.0 Impairment of property, plant and equipment 0.7 1.9 1.9 - Impairment of intangible assets 292.0 327.3 348.0 59.3 Impairmen

  34. Slide 34: Normalised Headline Earnings Bridge

    APPENDIX 5 | NORMALISED HEADLINE EARNINGS BRIDGE FOREX LOSSES DILUTE NHEPS -10% -16% -R715m -R1 288m 7 946 573 NHEPS = 1499 cents -744 NHEPS decline = -10% 7 373 Share buy-back benefited NHEPS by +2% 5 48 -633 6 657 -99 134 FY 2022 Fx impact FY 2022 CER ǂ Normalised Depreciation Amortisation Forex N

  35. Slide 35: Currency Mix

    APPENDIX 6 | CURRENCY MIX SIGNIFICANT EMERGING MARKET CURRENCY VOLATILITY IN FY 2023 FY 2023 FY 2022 Currency Normalised Normalised FY 2023 FY 2022 contribution Revenue EBITDA Revenue EBITDA average rate average rate % change EUR 30% 17% 31% 22% 18.61 17.14 9% ZAR 15% 9% 17% 11% AUD 15% 22% 14% 18%

  36. Slide 36: Net Working Capital

    APPENDIX 7 | NET WORKING CAPITAL LOWER WORKING CAPITAL CASH OUTLFOW IN H2 2023 3% Cash outflow +R1 157m 5 320 650 832 415 22 210 326 Commercial Pharma 258 Heparin 21 468 248 Other manufacturing 1 910 19 558 H1 2023 Fx impact H1 2023 CERǂ Inventory Trade Trade payables Net other Non cash FY 2023 Repo

  37. Slide 37: Effective Tax Rates

    APPENDIX 8 | EFFECTIVE TAX RATES INCREASED NORMALISED EFFECTIVE TAX RATE IN FY 2023 24.0% 22.0% 19.9% 20.2% 20.2% 20.0% 17.6% 18.0% 16.9% 16.4% 16.0% 14.0% 12.0% 10.0% FY 2021 FY 2022 FY 2023 Group effective tax rate Group normalised effective tax rate  Increase in normalised effective tax rate in

  38. Slide 38: Operating Cash Flows

    APPENDIX 9 | OPERATING CASH FLOWS OPERATING CASH CONVERSION RATE IN H2 2023 OF 115% FY 2023 FY 2022 % change H1 2023 Cash operating profit 11 300 10 023 13% 5 312 Changes in working capital (3 358) (2 652) -27% (2 168) Cash generated from operations 7 942 7 371 8% 3 144 Net finance costs paid (808)

  39. Slide 39: Capital Expenditure

    APPENDIX 10 | CAPITAL EXPENDITURE STERILE CAPEX EXPANSION PROJECT ON TRACK 2 300 2 230 1 963 PPE Capex 700 818 1 700  Sterile expansion project plan in South Africa is progressing to plan and is 500 well poised to take advantage of new third party manufacturing opportunities  Planned Capex expecte

  40. Slide 40: Net Financing Costs

    APPENDIX 11 | NET FINANCING COSTS RECONCILIATION OF NORMALISED TO REPORTED NET FINANCING COSTS R’million FY 2023 H2 2023 H1 2023 FY 2022 Net interest paid (591) (338) (253) (468) Effective interest rate for the period* 3.21% 3.55% 2.83% 2.92% Foreign exchange (losses)/gain (434) (200) (234) 184 Noti

  41. Slide 41: Net Borrowings

    APPENDIX 12 | NET BORROWINGS WELL BALANCED BORROWINGS REPAYMENT PROFILE 18.370 18.751  At 30 June 2022, Aspen had in place syndicated debt facilities 4.827 7.907 totaling the equivalent of R17,1 billion which were due to mature on 16.064 1 July 2023 (the “Maturing Facilities”). R8,4 billion of the

  42. Slide 42: Net Borrowings Bridge

    APPENDIX 13 | NET BORROWINGS BRIDGE WEAKER ZAR INCREASES REPORTED NET BORROWINGS. 1% REDUCTION IN CERǂ BORROWINGS -1% 18 609 18 370 Leverage ratio well below targeted levels at 1.9x 1 455 2 545 16 064 -5 520 3 181 309 336 FY 2022 Fx impact FY 2023 CERǂ Cash flows Other Deferred PPE and IP spend Divi

  43. Slide 43: Prior Year Transactions

    APPENDIX 14 | PRIOR YEAR TRANSACTIONS DEFERRED CONSIDERATION PAYMENTS R'million FY 2023 Disposal of the European Thrombosis assets – volume incentive payments and other transaction costs (441) Disposal of Japanese business – supply rebate payments (134) Disposal of Japanese business – uninterrupted

  44. Slide 44: Capital Allocation

    APPENDIX 15 | CAPITAL ALLOCATION 1 PPE capex and IP development 2 Bolt-on acquisitions & disposals of IP & businesses * 3 Dividend paid 4 Larger acquisitions & disposals R3 181 million R309 million No significant R1 455 million invested net outflow outflow Ensure business Inherent to renewal of Divi

Aspen Pharmacare Holdings — FY2023 Earnings Presentation on 6ix